(19)
(11) EP 2 535 353 A8

(12) CORRECTED EUROPEAN PATENT APPLICATION
Note: Bibliography reflects the latest situation

(15) Correction information:
Corrected version no 1 (W1 A1)

(48) Corrigendum issued on:
20.02.2013 Bulletin 2013/08

(88) Date of publication A3:
19.12.2012 Bulletin 2012/51

(43) Date of publication:
19.12.2012 Bulletin 2012/51

(21) Application number: 12181684.7

(22) Date of filing: 12.11.2008
(51) International Patent Classification (IPC): 
C07K 16/24(2006.01)
A61P 19/02(2006.01)
A61P 35/02(2006.01)
 A61P 11/00(2006.01)
A61P 17/06(2006.01)
(84) Designated Contracting States:
AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MT NL NO PL PT RO SE SI SK TR
Designated Extension States:
BA RS

(30) Priority: 13.11.2007 JP 2007294945
14.02.2008 WO PCT/JP2008/052471

(62) Application number of the earlier application in accordance with Art. 76 EPC:
08848696.4 / 2215119

(71) Applicants:
  • Evec Inc.
    Sapporo 060-0042 (JP)
  • Boehringer Ingelheim International GmbH
    55216 Ingelheim am Rhein (DE)

(72) Inventors:
  • Takada, Kenzo
    Sapporo 060-0042 (JP)
  • Nakajima, Kantou
    Sapporo 060-0042 (JP)
  • Kistler, Barbara
    55216 Ingelheim am Rhein (DE)
  • Park, John
    55216 Ingelheim am Rhein (DE)

(74) Representative: HOFFMANN EITLE 
Patent- und Rechtsanwälte Arabellastrasse 4
81925 München
81925 München (DE)

 
Remarks:
This application was filed on 24-08-2012 as a divisional application to the application mentioned under INID code 62.
 


(54) Monoclonal antibodies that bind to hGM-CSF and medical compositions comprising same


(57) Disclosed herein are anti-hGM-CSF monoclonal antibodies and antigen-binding fragments of such antibodies, with improved neutralizing capacity to hGM-CSF activity. Pharmaceutical compositions comprising such an antibody or antigen-binding fragment are also provided. The present invention is useful for the treatment of various diseases that are associated with aberrant expression of hGM-CSF.